Late-Breaking Science - International Stroke Conference
Pre-Cons and Stroke Nursing Symposia: February 3, 2026
Sessions: February 4–6, 2026
Ernest N. Morial Convention Center | New Orleans, Louisiana
Sessions: February 4–6, 2026
Ernest N. Morial Convention Center | New Orleans, Louisiana
The most anticipated studies of the year!
See the newest study results and discussions during International Stroke Conference 2026! Be the first to know results from CHOICE2; FASTEST; CREST-2; OCEANIC-STROKE; OPTION; ATTENTION LATE; TNK-PLUS; EMBOLISE and many, many, more.
PLEASE NOTE: All Late-Breaking Science Main Event and Concurrent Abstract Sessions are embargoed to the date and time of presentation.
All times listed are Central Standard Time (CST) (UTC -6).
Late-Breaking Science Main Event Sessions
Opening Main Event
11:00 a.m. to 12:30 p.m. CST
| Time | Activity |
|---|---|
| 11:45 a.m. | CHOICE2 - LB001. The Chemical Optimization of Cerebral Embolectomy (CHOICE2) Trial: Main Results Angel Chamorro, HOSPITAL CLINIC BARCELONA, Barcelona, Spain |
| 11:57 a.m. | FASTEST - LB002. Recombinant Factor VIIa for Spontaneous Intracerebral Hemorrhage within Two Hours of Onset. The FASTEST Trial Joseph P Broderick, University of Cincinnati, Cincinnati, OH |
| 12:09 p.m. | CREST-2 - LB003. The Effect of Treatment on Cognitive Function in Patients with Asymptomatic Carotid Artery Stenosis: The CREST-2 Trial Ronald M Lazar, Univ of Alabama at Birmingham, Birmingham, AL |
Thursday Main Event
11:00 a.m. to 12:30 p.m.
| Time | Activity |
|---|---|
| 11:15 a.m. | OCEANIC-STROKE - LB009. Factor XIa Inhibition with Asundexian in Acute Non-Cardioembolic Stroke or High-Risk Transient Ischemic Attack: Primary Results of the OCEANIC-STROKE Trial Mukul Sharma, Population Health Research Institute, Hamilton, ON, Canada |
| 11:27 a.m. | OPTION - LB010. Tenecteplase for acute non-large vessel occlusion at 4.5-24 hours Junwei Hao, Xuanwu Hospital, Beijing, China |
| 11:39 a.m. | ATTENTION LATE - LB011. Intravenous Tenecteplase Plus Endovascular Thrombectomy Versus Endovascular Thrombectomy Alone on 4.5 to 24 Hours After Stroke Due to Basilar Artery Occlusion -a Multicenter, Randomized Controlled, Clinical Trial (ATTENTION LATE) Rui Li, The First Affiliated Hospital of USTC, Hefei, China |
| 11:51 a.m. | TNK-PLUS - LB012. Endovascular Treatment With or Without Preceding Intravenous Tenecteplase in Patients with Late-Window Acute Ischemic Stroke Due to Middle Cerebral Artery Occlusion (TNK-PLUS): A Multi-Center, Prospective, Open-Label, Blinded Endpoint, Phase 3, Randomized Controlled Trial Yunyun Xiong, Beijing Tiantan Hospital, Beijing, China |
| 12:03 p.m. | EMBOLISE - LB013. The EMBOLISE Study: Embolization of the Middle Meningeal Artery with ONYXTM Liquid Embolic System In the Treatment of Subacute and Chronic Subdural HEmatoma Jared Knopman, Weill Cornell Medical College, New York, NY |
| 12:15 p.m. | LB014. Tirofiban for Branch Atheromatous Disease-Related Stroke: A Randomized, Double-Blind, Placebo-Controlled Trial Yilong Wang, Beijing Tiantan Hospital, Beijing, China |
Closing Main Event
11:00 a.m. to 1:20 p.m.
| Time | Activity |
|---|---|
| 11:45 a.m. | SPAN2 - LB030. Final Results of the SPAN2 Trial Patrick D Lyden, USC, Los Angeles, CA |
| 11:57 a.m. | I-ACQUIRE - LB031. The I-ACQUIRE Trial of Constraint Induced Movement Therapy for Infants/Toddlers with Perinatal Arterial Ischemic Stroke Sharon Landesman Ramey, Fralin Biomedical Research Inst., Roanoke, VA |
| 12:09 p.m. | LFAIS - LB032. Loberamisal for Acute Ischaemic Stroke (LFAIS): A multicenter, randomized, double-blind, parallel, placebo-controlled phase 3 clinical trial Shuya Li, Beijing Tiantan Hospital, Beijing, China |
| 12:21 p.m. | LB033. LT3001 Improves Functional Outcomes in Disabling Acute Ischemic Stroke: Results from Two Phase 2 Trials Thomas Devlin, CHI Memorial Neuroscience Institute / Morehouse School of Medicine, Chattanooga, TN |
| 12:33 p.m. | CONCERN - LB034. Efficacy and Safety of Chuanzhi Tongluo Capsule for Acute Ischemic Stroke Patients without Large or Medium-Sized Vessel Occlusion (CONCERN): A Multicenter Double-blind Randomized Control Trial Dahong Yang, Xinqiao Hospital and The Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China |
| 12:45 p.m. | LB035. Endovascular Treatment of Medium Vessel Occlusion Strokes with Moderate or Higher Clinical Severity Chunrong Tao, USTC, HeFei, China |
Late-Breaking Science Concurrent Oral Abstract Sessions
Late-Breaking Science Oral Abstracts I
5:00 p.m. to 6:00 p.m.
| Time | Activity |
|---|---|
| 5:00 p.m. | CREST-2 - LB004. Annual Stroke Risk for Medical Management Patients with High-Grade Carotid Stenosis: CREST-2 with Comparisons to SPACE-2 and ECST-2 James F Meschia, Mayo Clinic Florida, Jacksonville, FL |
| 5:10 p.m. | SOLO-ESUS - LB005. Efficacy and Safety of a Patch-Type Cardiac Monitor for Diagnosing Paroxysmal Atrial Fibrillation in Embolic Stroke of Undetermined Source Patients with Left Atrial Enlargement (SOLO-ESUS): A Randomized Controlled Trial Bum Joon Joon Kim, ASAN MEDICAL CENTER, Seoul, Korea (the Republic of) |
| 5:20 p.m. | MIRACLE - LB006. MIRACLE: Methylprednisolone as Adjunct to Endovascular Thrombectomy for Patients with Acute Ischemic Stroke with Large Infarct: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Qianqian Lin, the first affiliated hospital of Fujian Medical University, Fuzhou, China |
| 5:30 p.m. | LB007. Anti-Inflammatory Mechanisms of Anti-Sdc2 Mab VB-001 Contributing to Neuroprotection After Ischemic Stroke Federico Corti, Yale University, New Haven, CT |
| 5:40 p.m. | LB008. Development and Evaluation of Anti-Matrix Metalloproteinase-12 Single-Chain Variable Fragment Antibodies as Potential Therapeutics for Ischemic Stroke Krishna Kumar Veeravalli, UIC College of Medicine Peoria, Peoria, IL |
Late Breaking Science Oral Abstracts II
2:30 p.m. to 3:30 p.m.
| Time | Activity |
|---|---|
| 2:30 p.m. | LB015. Factors Associated with Sex Differences in Cognitive Decline: A Pooled Cohort Analysis of ARIC, CHS, FOS, MESA, and CARDIA in the BP COG Study Brian Stamm, University of Michigan, Ann Arbor, MI |
| 2:40 p.m. | NS-STROKE - LB016. Normal Saline Infusion for Stroke after Intravenous Thrombolysis: A Randomized Multicenter Trial Jiayue Ding, Tianjin Medical University General Hospital, Tianjin, China |
| 2:50 p.m. | MAESTOSO - LB017. The MLC1501 Study Assessing Efficacy in Post-STrOke Subjects with MOtor Deficits (MAESTOSO) Christopher Chen, NATIONAL UNIVERSITY OF SINGAPORE, Singapore, Singapore |
| 3:00 p.m. | LB018. TIME EFFECTS OF LONG-TERM BP LOWERING AFTER INTRACEREBRAL HEMORRHAGE: POOLING OF INDIVIDUAL PATIENT DATA FROM PROGRESS, RESPECT, ESPIRIT AND TRIDENT TRIALS Craig Stuart Anderson, THE GEORGE INSTITUTE FOR GLOBAL HEA, Camperdown, NSW, Australia |
| 3:10 p.m. | EMMA-Can - LB019. EMMA-Can: A Three-Arm Study Comparing Prospective Registry and Randomized Trial Designs for Middle Meningeal Artery Embolization in Chronic Subdural Hematoma Jai J Shankar, University of manitoba, Winnipeg, MB, Canada |
Late Breaking Science Oral Abstracts III
Beyond the Plenary: Deeper Dives into OCEANIC-STROKE, CREST-2, and FASTEST
3:45 p.m. to 4:45 p.m.
| Time | Activity |
|---|---|
| 3:45 p.m. | OCEANIC-STROKE - LB020. Qualifying Ischemic Stroke Subtypes and Response to Asundexian: Prespecified Secondary Analysis of the OCEANIC-STROKE Trial Ashkan Shoamanesh, Population Health Research Institute, Hamilton, ON, Canada |
| 3:55 p.m. | CREST-2 - LB021. Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis–Hemodynamics -- Main Results Randolph S Marshall, Columbia University, New York, NY |
| 4:05 p.m. | CREST-2 - LB022. Assessment of the Potential for Stroke Risk Reduction Following Carotid Revascularization to Extend Beyond 4 Years: CREST-2 George Howard, University of Alabama, Birmingham, AL |
| 4:15 p.m. | FASTEST - LB023. Recombinant Factor VIIa Treatment Within Two Hours of Spontaneous Intracerebral Hemorrhage Onset Decreases Hematoma Expansion and Improves 90-Day Outcomes in CT Angiography Spot Sign–Positive Patients Andrew M Naidech, Northwestern University, Chicago, IL |
| 4:25 p.m. | FASTEST - LB024. Exploring the Optimal Time Window for Treatment with Recombinant Activated Factor VII (rFVIIa) In Patients with Intracerebral Hemorrhage James C Grotta, Memorial Hermann Hospital - Texas Medical Center, Houston, TX |
Late Breaking Science Oral Abstracts IV
5:00 p.m. to 6:00 p.m.
| Time | Activity |
|---|---|
| 5:00 p.m. | PROCHASE - LB025. Propranolol for Prevention of Stroke-associated Pneumonia in Intracerebral Hemorrhage (PROCHASE): A Multicenter, Randomized, End Point Blind Trial Fu-Dong Shi, Beijing Tiantan Hospital, Beijing, China |
| 5:10 p.m. | ARPEGGIO - LB026. ARPEGGIO phase 2 trial of Scp776, a First-in-Class Cerebroprotective Agent in Patients Undergoing Endovascular Thrombectomy: Pre-specified Efficacy Analyses Eva Mistry, University of Cincinnati, Cincinnati, OH |
| 5:20 p.m. | FUTURE - LB027. Sublingual Cilostazol and Dexborneol for the Treatment of Acute Ischemic Strokeļ¼A Randomized Clinical Trial Yilong Wang, Beijing Tiantan Hospital, Beijing, China |
| 5:30 p.m. | REACT - LB028. Safety and Efficacy of Adjunctive Intra-arterial adenosine following Successful Endovascular Thrombectomy in Patients with Large Vessel Occlusion Acute Ischemic Stroke (REACT) Trial Zhenhua Zhou, Southwest Hospital, Chongqing, China |
| 5:40 p.m. | TRACE-5 - LB029. Early vs. Late Time Window Tenecteplase for Basilar Artery Occlusion, With or Without Thrombectomy: a Subgroup Analysis from the TRACE-5 Trial Yunyun Xiong, Beijing Tiantan Hospital, Beijing, China |